Post hoc analysis of 1766 patients with cancer-associated VTE on extended apixaban: anaemia and/or thrombocytopenia (SHR 1.93), age 75 or older (1.51), PE as index event (1.47) and male sex (1.38) predicted clinically relevant bleeding, regardless of dose.
Secondary analysisn = 1,766
Mahé et al. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial